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2.8, p=O.O5) were independently associated with 
increased rejection risk. Older age was associated with 
decreased risk (RR: 0.97,95% CI 0.95 to 0.99,p<O.O1). 
Conclusion: Among factors associated with rejection, 
use of prophylactic ganciclovir shows a significant 
reduction in biopsy proven rejection in OLT. In the 
current era of organ transplantation with the use of 
prolonged oral ganciclovir prophylaxis, with or without 
CMVIG, the incidence of CMV disease, mortality and 
rejection is dramatically reduced. 
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Objectives: The follow-up some infectious complications 
at the patients with diabetic nephropathy after renal 
allotransplantation 
Methods: Laboratory diagnosis was performed by PCR- 
primers to MIE region of CMV with product 500 b.p., 
to BMRF-1 region of Epstein-Barr virus (EBV) with 
product 290 b.p. and to adherence factor region of 
Candida albicans with product 500 b.p., to L-l region of 
HHV-6 with product 379 b.p. 
Results: The blood of 59 patients after renal allotrans- 
plantation were assayed. Among them 57 had 1 type 
diabetes and 2 had II type diabetes. Cytomegalovirus 
(CMV) DNA was revealed in the blood of 39 (66,1%) 
patients as single herpes-virus infection at 14 to 15 days 
after transplantation with minimal clinical symptoms 
(indisposition, subfebrile temperature, leukopenia, 
symptoms of rejection), besides 3 patients, who had very 
acute CMV-pneumonia for a long time. After treatment 
by gancyclovir the symptoms of diseases disappeared 
and CMV DNA cleaned. No one of 67 donors had CMV 
DNA in blood. Among 79 usual renal recipients CMV 
DNA had 19 (24%) with different clinical symptoms. In 
the blood of 1 patient DNA of C. albicans was detected. 
The diagnosis was confirmed by bacteriological method. 
This patient had acute fungal pneumonia. After treat- 
ment by amfotemycin B symptoms of pneumonitis dis- 
appeared and DNA of C. albicans cleaned. In the blood 
of 17 (28.9%) patients EBV DNA was revealed without 
other infections. This patients had diarrhea, subfebrile 
temperature and the short pains in the joints. After 
treatment by acyclovir, zovirax or zaditen the symptoms 
of diarrhea disappeared and the conditions of patients 
get well. 20% of healthy donors had EBV DNA in 
blood. One diabetic patient, who had DNAs of CMV, 
HHV-6 and EBV, was a very severe one and suffered 
with acute CMV disease 6 weeks later of the HHV-6 and 
EBV DNA disappearance. 
Conclusion: Diabetic patients have infectious complica- 
tions much more often and with more severe clinical 
symptoms as compared to usual patients after renal 
transplantation. The diseases begin earlier (at 14-15 
days), and therefore we recommend to begin the 
preventive therapy at 7-9 days after transplantation. 
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The aim of the study was to assess the oral cavity status 
and identify the oral microorganisms in the kidney 
allograft recipients under chronic immunosuppression 
(TX), in the recipients with type I diabetes (Txd) and in 
the control patients (C) without systemic diseases. 
Forty-five patients, 20 to 65 years old, were analysed. 
Swabs and samples taken randomly from 5 sites of 
periodontium and dental pockets of each patients were 
used for microscopical studies and cultured to identify 
bacteria and fungi. 
Among the TX and Txd patients the oral alterations 
were observed (mucosal inflammation, gingival 
hyperplasia, periodontitis). 
The microscopical examinations and cultures showed 
the presence of various species of the fecal bacteria 
(Enterococcus faecalis, E. faecium, Enterobacteriaceae, 
Escherichia coli) and the fungi (identified as various 
strains of Candida albicans); the oral protozoans: 
Trichomonas tenax and Entamoeba gingivalis were also 
found. Prevalence of the bacteria was higher in the Txd 
and TX groups (50% and 43.7%) respectively) than in the 
control patients (5.8 %).The fungi were found in 41.5% 
of the Txd, 37.5% of TX and in 17.5% of C patients. 
Prevalence of the oral protozoans was 8.5% in Txd, 12.5 
in TX and 17.5% in the C patients. 
Our studies show that the species composition of the 
microorganisms is clear changed in the oral cavity of the 
patients with serious metabolic disabilities and decreased 
resistance connected with the systemic disease, in 
comparison to the control patients. High prevalence of 
the bacterial and fungal opportunistic species in the 
mouth of the patients under chronic immunosuppression 
indicates on a major risk for subsequent-local or general- 
infections that may cause further deterioration of the 
health in the kidney allograft recipients. 
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Background: Cytomegalovirus infection and disease are 
potential risk factors for acute allograft rejection in renal 
transplant recipients. 
Methods: From October 1994 to July 1997, 477 con- 
secutive renal allograft recipients (397 first transplants 
and 80 retransplants) were included in the study. 
Cytomegalovirus infection (cytomegalovirus pp65 
antigen in leukocytes) and disease (infection and clinical 
symptoms or signs of disease) were examined pro- 
spectively for 3 months. No cytomegalovirus prophylaxis 
was given, and cytomegalovirus disease was treated 
with i.v. ganciclovir. The retransplantation of 4 patients 
transplanted twice during the study and 22 patients 
receiving kidneys from HLA-identical siblings were 
excluded from statistical analysis. Rejections were 
evaluated clinically (277 (61%)) and 173 (38%) also had 
a biopsy verified rejection. 
Results: Cytomegalovirus infection occurred in 64% of 
the patients and 24% experienced cytomegalovirus 
disease. In a multiple time-dependent Cox analysis 
independent significant predictors for clinical acute 
rejections were cytomegalovirus infection, RR=1.6 
(1.1-2.5, p=O.O2), cytomegalovirus disease, RR=2.5 
(1.2-5.l,p=O.O1). Among 173 patients with biopsy veri- 
fied rejection 72% of the patients had tubulointerstitial 
rejection whereas 28% had a vascular rejection. 
cytomegalovirus disease, but not cytomegalovirus in- 
fection was a predictor of tubulointerstitial rejection, 
RR=3.1 (l.l-9.3,p=O.O4). 
Conclusion: Cytomegalovirus infection and disease are 
independent risk factors for clinically acute rejection 
in kidney risk factor for biopsy verified acute tubulo- 
interstitial rejection in kidney allograft recipients. 
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Introduction: Cytomegalovirus (CMV) disease occurs 
frequently after solid organ transplantation and has 
been associated with decreased patient and allograft 
survival. IVIg have been used in organ transplantation 
in combination with antiviral agents to treat established 
CMV disease. However, only limited data in heart trans- 
planted patients with secondary hypogammaglobu- 
linemia exist. 
Patients and Methods: We assessed the overall pre- 
valence of significant hypogammaglobulinemia in the 
post-transplantation period after heart transplantation. 
We present data on 5 heart transplanted patients with 
recurrent CMV infection, four of whom developed 
gastrointestinal disease. One of the patients associated 
acute graft rejection. An immunologic evaluation 
showed hypogammaglobulinemia (mean IgG levels: 
323+40 mg/dl (n.v. 700-1600 mg/dl)) in all the patients. 
The mean absolute number of CD4+ T-cells and 
B lymphocyte counts were 429?233 and 67240 cells/ 
mm3, respectively. IVIg (Flebogamma@) 200-400 mg/kg 
every 21 days plus antiviral treatment with gancyclovir 
was administered to the patients. After treatment the 
patients were followed-up for a mean period of 12 
months. 
Results: IVIg treatment, in combination with antiviral 
therapy, proved able to control CMV disease. There was 
a favorable clinical response and the patients became 
free of gastrointestinal symptoms. Detection of CMV 
antigens was negative after treatment. 
Conclusions: Even if our survey was limited to only 
five cases, the results indicated that addition of IVIg to 
antiviral chemotherapy might improve outcome in heart 
transplanted patients with CMV disease and hypo- 
gammaglobulinaemia. 
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Objective: To assess if keeping a previously placed IC is 
associated with an increase in morbidity in patients 
undergoing APSCT. 
Methods: We reviewed all pts who underwent APSCT 
with an IC in place from 3/97 to l/02. We compared these 
pts with a control group (no IC in place) that was 
matched by disease, age, and sex. 
Results: 43 pts (IC group) were matched with 43 
controls (no IC). In both groups the age (mean 40 years 
old), the sex distribution (58% females), and the 
duration of neutropenia (mean 8 days) were the same. 
Underlying malignancies included multiple myeloma 
(14 and 12) lymphoma (22 and 24) leukemia (3 and 3) 
and others (4 and 4) in the IC and no IC groups, 
respectively. Antibacterial and antifungal prophylaxis 
were used in 18 and 23 pts in the IC group vs 10 and 17 
pts in the no IC group (P=NS). The IC were used in 20 
of 43 pts within the 60 days of transplantation The 
endpoints shown in the table were used as markers of 
morbidity: 
